

Our ref: IG/FOI/FOI.057.26

23 February 2026

Sent via email to: [REDACTED]

Dear [REDACTED]

Request under the Freedom of Information Act 2000

I write further to your request for information which was received on 09 February 2026, to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) does not hold the information that you require. For ease of reference your request is set out below and the Health Board's response follows.

Your Freedom of Information (FOI) Request:

I am writing to you under the Freedom of Information Act to request the following information:

Q1. How many patients has your Trust treated in the past 12 months (February 2025 - January 2026, or latest 12 months available) for Mantle Cell Lymphoma (MCL) (excluding patients being monitored but not undergoing active treatment)? In case you do not treat MCL, which other Trust do you refer patients needing treatment to?

Q2. How many Mantle Cell Lymphoma (MCL) patients have been treated by the Trust in the past 6 months (August 2025 - January 2026, or latest 6 months available) on the following treatments:

- BR (Bendamustine + rituximab)
- VR-CAP (Bortezomib, Rituximab, Doxorubicin, Cyclophosphamide and prednisolone)
- R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone)
- R-maxi-CHOP or Nordic Protocol (R-CHOP alternated with Rituximab+ High-dose Cytarabine)
- CVP (cyclophosphamide, vincristine and prednisolone)

- Brukinsa (zanubrutinib)
- Imbruvica (ibrutinib)
- Velcade (bortezomib) + chemotherapy
- Tecartus (brexucabtegene autoleucel)
- R-BAC (rituximab, bendamustine and cytarabine)
- R-DHAP (rituximab + cytarabine + cisplatin + dexamethasone)
- Any other systemic anti-cancer therapy
- Wait and watch (monitoring only, no active treatment)

Q3. How many Mantle Cell Lymphoma (MCL) new patients have been initiated by the Trust in the past 6 months (August 2025 - January 2026, or latest 6 months available) on the following treatments:

For this question, please only count patients that have received the below treatments for the first time.

- BR (Bendamustine + rituximab)
- VR-CAP (Bortezomib, Rituximab, Doxorubicin, Cyclophosphamide and prednisolone)
- R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone)
- R-maxi-CHOP or Nordic Protocol (R-CHOP alternated with Rituximab+ High-dose Cytarabine)
- CVP (cyclophosphamide, vincristine and prednisolone)
- Brukinsa (zanubrutinib)
- Imbruvica (ibrutinib)
- Velcade (bortezomib) + chemotherapy
- Tecartus (CAR-T)
- R-BAC (rituximab, bendamustine and cytarabine)
- R-DHAP (rituximab + cytarabine + cisplatin + dexamethasone)
- Any other systemic anti-cancer therapy
- Wait and watch (monitoring only, no active treatment)

Q4. If your Trust does treat Mantle Cell Lymphoma (MCL) patients, do you currently participate in any ongoing clinical trials for the treatment of MCL? If yes, please can you provide details of the ongoing trials.

Powys Response:

I can confirm that Powys Teaching Health Board (PTHB) does not directly diagnose, treat or test patients for Mantle Cell Lymphoma (MCL). PTHB is a non-acute care provider and therefore does not directly provide an oncology service or undertake clinical trials. Patients are treated by providers outside of Powys. PTHB commissions services from a number of Welsh health boards and English provider organisations.

Due to the complex nature of PTHB's commissioning arrangements, not all of our providers indicate the indication for use for each episode of care where these drugs are used. For this reason, PTHB does not hold the data relating to your request, however, the health board is working closely with providers to ensure that this information can be provided in the future. We therefore recommend that you approach our provider organisations directly for this information. The table below lists the main health boards and NHS Trust from which we

commission health services for Powys residents. Please note that all providers may not necessarily offer services that fall within the definition of your request.

Health Trust/Organisation	FOI Contact Details
Gloucestershire Hospitals NHS Foundation Trust	ghn-tr.foi@nhs.net
Sandwell and West Birmingham NHS Trust	swb-tr.SWBH-GM-FOIRequests@nhs.net
The Shrewsbury and Telford Hospital NHS Trust	sath.foi@nhs.net
The Royal Wolverhampton NHS Trust	rwh-tr.foi@nhs.net
Worcestershire Acute Hospitals NHS Trust	wah-tr.FOI@nhs.net
Wye Valley NHS Trust	Freedom.Information@wvt.nhs.uk

Health Board/Organisation	FOI Contact Details
Aneurin Bevan University Health Board	FOI.ABB@wales.nhs.uk
Betsi Cadwaladr University Health Board	bcu.foi@wales.nhs.uk
Cardiff & Vale University Health Board	FOI.Requests@wales.nhs.uk
Cwm Taf Morgannwg University Health Board	Freedomofinformation@wales.nhs.uk
Hywel Dda University Health Board	FOI.hyweldda@wales.nhs.uk
Swansea Bay University Health Board	FOIA.Requests@wales.nhs.uk
Velindre University NHS Trust	Foi.vunhst@wales.nhs.uk

If you have queries or any concerns, contact details are given at the top of the letter. Please remember to quote the reference number above in any future communications. If you are dissatisfied with the handling or response to your request and wish to ask for a review of this, please contact us and we will arrange for this to be done.

Further information is available from the Information Commissioner's Office who can be contacted at:

Address: Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH.

Telephone: 0330 414 6421

Complaints Portal: www.ico.org.uk/foicomplaints

Web site: <https://ico.org.uk/>

Re-use of Public Sector Information

All information supplied by the Health Board in answering a request for information (RFI) under the Freedom of Information Act 2000 will be subject to the terms of the Re-use of Public Sector Information Regulations 2015.

Under the terms of the Regulations, the Health Board will licence the re-use of any or all information supplied if being used in a form and for the purpose other than which it was originally supplied. This license for re-use will be in line with the requirements of the Regulations and the licensing terms and fees as laid down by the Office of Public Sector Information (OPSI). Most licenses will be free; however, the Health Board reserves the right, in certain circumstances to

charge a fee for the re-use of some information which it deems to be of commercial value.

Further information including a sample license terms and fees can be found at [Open Government Licence](#).

Yours sincerely



Kate Wright
Executive Medical Director

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi.

We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay.